

A combined antitumor strategy of separately transduced mesenchymal stem cells with soluble TRAIL and IFN β produces a synergistic activity in the reduction of lymphoma and mice survival enlargement

ADRIANA G. QUIROZ-REYES^{1*}, CARLOS A. GONZÁLEZ-VILLARREAL^{2*},
HERMINIA MARTÍNEZ-RODRIGUEZ¹, SALVADOR SAID-FERNÁNDEZ¹,
MARIO CÉSAR SALINAS-CARMONA³, ALBERTO Y. LIMÓN-FLORES³,
ADOLFO SOTO-DOMÍNGUEZ⁴, GERARDO PADILLA-RIVAS¹,
ROBERTO MONTES DE OCA-LUNA⁴, JOSE F. ISLAS⁴ and ELSA N. GARZA-TREVIÑO¹

¹Department of Biochemistry and Molecular Medicine, Faculty of Medicine, Autonomous University of Nuevo Leon, Monterrey, Nuevo León 64460; ²Laboratory of Molecular Genetics, Department of Basic Sciences, University of Monterrey, Monterrey, Nuevo León 66238; Departments of ³Immunology and ⁴Histology, Faculty of Medicine, Autonomous University of Nuevo Leon, Monterrey, Nuevo León 64460, Mexico

Received January 14, 2022; Accepted March 29, 2022

DOI: 10.3892/mmr.2022.12722

Abstract. As the understanding of cancer grows, new therapies have been proposed to improve the well-known limitations of current therapies, whose efficiency relies mostly on early detection, surgery and chemotherapy. Mesenchymal stem cells (MSCs) have been introduced as a promissory and effective therapy. This fact is due to several useful features of MSCs, such as their accessibility and easy culture and expansion *in vitro*, and their remarkable ability for ‘homing’ towards tumors, allowing MSCs to exert their anticancer effects directly into tumors. Additionally, MSCs offer the practicability of being genetically engineered to carry anticancer genes, increasing their specificity and efficacy for fighting tumors. In the present study, the antitumoral efficacy and post-implant survival of mice bearing lymphomas implanted intratumorally were determined using mouse bone marrow-derived (BM)-MSCs transduced with soluble TRAIL (sTRAIL), full length TRAIL (flTRAIL), or interferon β (IFN β), naïve BM-MSCs,

or combinations of these. The percentage of surviving mice was determined once all not-implanted mice succumbed. It was found that the percentage of surviving mice implanted with the combination of MSCs-sTRAIL and MSCs-IFN β was 62.5%. Lymphoma model achieved 100% fatality in the non-treated group by day 41. On the other hand, the percentage of surviving mice implanted with MSCs-sTRAIL was 50% and with MSCs-IFN β 25%. All the aforementioned differences were statistically significant ($P < 0.05$). In conclusion, all implants exhibited tumor size reduction, growth delay, or apparent tumor clearance. MSCs proved to be effective anti-lymphoma agents; additionally, the combination of soluble TRAIL and IFN β resulted in the most effective antitumor and life enlarging treatment, showing an additive antitumoral effect compared with individual treatments.

Introduction

Cancer is one of the most lethal diseases. Conventional treatment consists of surgery, chemotherapy and radiotherapy. This therapeutic scheme, based on 5FU and oxaliplatin is useful only when cancer is detected early, but it lacks specificity and is not practical in the presence of metastases (1). Moreover, this therapy has remained mostly unchanged for decades. Besides, all the aforementioned treatments, and particularly radiotherapy and chemotherapy, produce severe harmful effects (2). Recently, new approaches that focus on cancer mechanisms to increase specificity in cancer cell elimination efficacy and safety are being intensively analyzed. Some of these new therapies introduce the use of nanoparticles, monoclonal antibodies, miRNAs, gene and cell therapy with the use of cells as delivery vectors for antitumoral proteins (3-10). All promise to be more specific, efficacious and safer than conventional treatments.

Correspondence to: Dr Elsa N. Garza-Treviño, Department of Biochemistry and Molecular Medicine, Faculty of Medicine, Autonomous University of Nuevo Leon, Ave. Francisco I. Madero and Dr Eduardo Aguirre Pequeño S/N, Monterrey, Nuevo León 64460, México
E-mail: egarza.nancy@gmail.com

*Contributed equally

Key words: mesenchymal stem cells, TNF α -related apoptosis-inducing ligand, interferon β , lymphoma, immunocompetent, lentivirus, cancer treatment

In the present study, engineered mesenchymal stem cells (MSCs) were used as antitumoral therapy, considering that MSCs gather several desirable features (11) as anticancer weapons, such as their abundance in tissues, particularly in bone marrow (BM) (12) and adipose tissue (13). Besides, these cells have the outstanding ability for 'homing' to the tumor microenvironment. Homing allows MSCs to exert their anticancer effects directly towards tumors (14). Nevertheless, a serious limitation for using MSCs as anticancer therapy is that it is hard to predict the naïve MSCs behavior in the tumor, as these cells, under the influence of the tumor microenvironment, can improve tumor growth (15-17). Thus, an alternative is needed that increases the anticancer potency of MSCs and reduces the risk of favoring cancer progression instead of fighting it. Achieving this goal is possible since MSCs offer the practicability of being genetically engineered to overexpress coded proteins and find and attack malignant cells. Therefore, engineering MSCs can ensure that these cells specifically attack malignant cells and overcome the naïve MSCs efficacy for fighting tumors. To transduce murine BM-MSCs, the murine soluble fraction of the TNF α -related apoptosis-inducing ligand (sTRAIL) and interferon β (IFN β) was chosen, considering the following features of each transgene: sTRAIL is a powerful anticancer protein extensively used due to the selective apoptotic effect that this protein induces in malignant cells. TRAIL targets the death receptors (DR)4 and DR5, which activate apoptosis by a caspase-8 derived process; the aforementioned receptors are mainly overexpressed by malignant cells (18,19). sTRAIL exerts its function once it has been trimerized and bound with cell receptors. However, Wong *et al* (19) pointed out that full-length (fl)TRAIL can induce apoptosis more efficiently than soluble (s)TRAIL. Interferon beta (IFN β) is a type I member of the interferon family with pleiotropic roles, including immunomodulator, antiproliferative and cancer-inhibitory activity (20). IFN β has already been examined and reported as an effective gene therapy agent (21); however, it was hypothesized in the present study that the combination of both proteins could increase the reach of monotherapy efficiency. To achieve this goal, a murine syngeneic model of lymphoma was used, with an immunocompetent strain (BALB/c) and BM-MSCs freshly obtained from mice belonging to the same BALB/c strain. The purpose of the present study was to determine the percentage of surviving mice and lymphoma reduction in mice implanted with MSCs carrying sTRAIL or IFN β transgenes and their combinations.

Materials and methods

Mice. BALB/c mice were born, grown and maintained in the Laboratory of Animal Experimentation of the Autonomous University of Nuevo Leon. Male mice aged 4 to 8 weeks were used to isolate BM-MSCs. A total of 72 female BALB/c mice (12 weeks old) weighing 19-22 g were used to induce solid lymphomas and evaluate the *in vivo* anti-lymphoma efficacy. From mice birth and throughout the experiments until the last mouse was euthanized, all animals were kept in individually ventilated cages at 25°C with sterilized air with EPA filters (UREAtac; LAB&Bio), with 50% humidity, ≤ 500 ppm of CO $_2$, ≤ 15 ppm of NH $_3$ and a light/dark cycle of 12/12 h. Access

to food (Labdiet 5001; LabSupply) and purified sterile water was provided *ad libitum*.

Lymphoma cells. The thymic lymphoma cell line L5178Y was used to produce lymphomas; the clone that was used (3.7.2C) was derived from the L5178YS cell line. *In vitro*, these cells grow in suspension; *in vivo*, when inoculated intramuscularly, they produce solid lymphomas, and when injected intraperitoneally, they grow abundantly and produce ascites. The L5178Y cell line was purchased from the American Type Culture Collection (cat. no. CRL-9518™; ATCC®) and cultured as instructed by the manufacturer. The culture medium was Dulbecco's modified Eagle's medium (DMEM) high glucose medium (4.5 g/l), 0.1% pluronic, 100 μ g gentamycin/ml, 2.5 μ g amphotericin B/ml, and 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.).

Lentiviral vectors. Lentiviral vectors were produced and provided by Cyagen Biosciences, Inc. as a gene delivery tool, named as follows: pLV[Exp]-EGFP/Neo-EF1A>{sMurTRAIL}, pLV[Exp]-EGFP/Neo-EF1A>mIfnb1[NM_010510.1], pLV[Exp]-EGFP/Neo-EF1A>{MurLL12-70p}. The lentiviral vectors were of 3rd generation and also included an integration cassette for G-418 (geneticin; Gibco; Thermo Fisher Scientific, Inc.) resistance for cell selection and a green fluorescent protein (GFP) gene to evaluate transgene integration.

MSC isolation and cell culture. BM-MSCs were obtained and characterized as previously described (22). Briefly, six mice were placed inside a CO $_2$ chamber to sacrifice them (70% vol/min); immediately after, their femurs and tibias were dissected under aseptic conditions. Their epiphysis was removed, and using a hypodermic needle (27 gauge), their BM was obtained by perfusing the shafts inner barrel with 500-1,000 μ l DMEM/Nutrient Mixture F-12 (DMEM F-12) medium supplemented (s) with 10% FBS, 100 μ g gentamicin/ml, and 2.5 μ g amphotericin B/ml (Gibco; Thermo Fisher Scientific, Inc.) and poured into T-25 cell culture flasks (Corning, Inc.). The first cell passage was accomplished as follows: The aforementioned preparations were incubated for 24 h at 37°C in a 5% CO $_2$ humid atmosphere. The expended medium and the non-adherent cells were discarded. The culture flasks with the adherent cells were replenished with 4 ml fresh medium and incubated as before until the cell monolayer reached 80% confluence (7-10 days). The second passage was performed by discarding the spent medium and incubating the cell monolayer with a solution of 0.25% trypsin and 0.1% EDTA (Gibco; Thermo Fisher Scientific, Inc.) in sterile phosphate-buffered saline (PBS), washing twice with PBS and inoculating 5x10 5 cells in a new culture flask with fresh 5 ml of supplemented DMEM F-12 and incubating it as before. The procedure described for the second passage was repeated in each of the following passages.

MSC characterization. The characterization of MSCs and the assays performed with them were accomplished with cell cultures from passage 3 or 4. MSCs were characterized by immunocytochemistry and their multipotency was evaluated (Fig. 1). Cells were fixed with methanol-acetone (1:1) at 4°C per 10 min. Regarding immunocytochemistry, CD90

and CD105 surface markers were investigated using specific monoclonal antibodies included in the mouse and rabbit specific HRP/DAB (ABC) detection IHC kit (cat. no. ab64264; Abcam). Antibodies were diluted in PBS to 1:200 (CD90) and 1:25 (CD105). MSC multipotency was examined by inducing the cells to differentiate to osteoblasts or chondroblasts, using the appropriate reagents in the Mouse Mesenchymal Stem Cell Functional Identification kit (cat. no. SC010; R&D Systems, Inc.) and following the manufacturer's instructions. The osteoblasts were identified by staining with the Von Kossa technique and chondroblasts with Alcian blue. Cells were fixed with 4% paraformaldehyde for 20 min at ambient temperature. In Von Kossa staining, slides were submerged in saturated lithium carbonate solution for 20 min, and then washed with water and submerged in a 5% silver nitrate solution. Slides were exposed to bright light for 60 min and then were submerged in 5% sodium thiosulfate solution for 5 min. Finally, the slides were counterstained with neutral red. In Alcian blue staining, the colorant was added at ambient temperature for 10 min, and then the slides were washed with water and counterstained with neutral red at ambient temperature for 2 min.

Construct design. All transgene constructs contained murine sequences of the genes of interest, a promotor cassette for Elongation Factor 1-Alpha (EF1- α) to allow a constitutive, high protein expression, and the Kozak consensus sequence (GCCGCCACC) (23). The constructs used in the present study were designed with Vector Builder software (Cyagen Biosciences, Inc.). The design of the sTRAIL transgene is presented in Fig. 2A. This design contained the sTRAIL nucleotide sequence codifying the amino acid fragment 118 to 291; an isoleucine zipper sequence to facilitate *in situ* TRAIL's trimerization (24,25), a furin specific cleavage site (CGCACC AAACGC), a signal sequence (SS) derived from *Gaussia* sp. (a copepod) luciferase (TGGGAGTCAAAGTTCTGTTTG CCCTGATCTGCATCGCTG-TGGCCGAGGCC) to conduct protein secretion (26) and Kozak's sequence. As revealed in Fig. 2B, besides EF1- α and Kozak's sequence, the construct used to perform the transduction of BM-MSCs with the flTRAIL transgene contained a nucleotide sequence coding its 1-291 amino acids. The entire flTRAIL was retracted from GeneBank (accession number U37522, URL: <https://www.ncbi.nlm.nih.gov/nuccore/U37522>). Regarding IFN β , the murine IFN β gene sequence was retracted from GeneBank (accession number NM_010510, URL: https://www.ncbi.nlm.nih.gov/nuccore/NM_010510). As demonstrated in Fig. 2C, the scheme of the IFN β transgene design was as follows: The complete IFN β nucleotide sequence was included and added with Kozak's sequence.

Transduction of murine BM-MSC. BM-MSCs (5×10^5) were seeded into T-25 culture flasks (Corning, Inc.) containing 5 ml DMEM F-12 supplemented with 10% FBS and incubated overnight under standard conditions, 50% confluency. Then, protamine sulfate (Sigma-Aldrich), 5 μ g/ml were added to the BM-MSC cultures. Each lentivirus preparation carrying sTRAIL, flTRAIL, or IFN β transgenes was added to separate BM-MSC cultures. The multiplicity of infection (MOI) employed was two viral particles/one BM-MSC (27). The BM-MSCs infected with the lentivirus vectors were incubated

overnight, to allow viral infection. Then, spent media was discarded and replenished with fresh DMEM-F12 and incubated 48 h before fluorescence analysis. Lentivirus integration was validated with fluorescence emitted by GFP, which was visualized with a fluorescence microscope (Eclipse 10i; Nikon Corporation) and a representative field photographed with a Sight DS-2MV (Nikon Corporation) digital camera. The selection of transduced BM-MSCs was accomplished by adding 200 μ g of geneticin/ml to the culture medium. Transduction efficiency was calculated by applying the following equation: % Transduction efficiency = BM-MSC-GFP/total BM-MSC $\times 100$. Where BM-MSC-GFP are transduced cells that exhibit a green fluorescent signal under the epifluorescence microscope. Total BM-MSC is the total number of cells detected by counting nuclei by fluorescence with DAPI (blue signal). Mounting medium Vectashield with DAPI (7 μ l) per slide was applied (Vecta Mount; Vector Laboratories, Inc.).

Protein extraction. Gene expression was validated by western blot analysis. BM-MSCs (5×10^5) transduced with sTRAIL, flTRAIL or IFN β were placed, separately, into T-75 flasks (Corning, Inc.), containing 10 ml of DMEM-F12 and incubated at 37°C with 5% CO₂ for 48 h and allowing 70% confluency. The spent medium was discarded, and then the cell culture flasks were replenished with 10 ml fresh supplemented media and incubated at 37°C with 5% CO₂ for 48 h. For soluble proteins (sTRAIL and IFN β), the spent medium was centrifuged at 4,000 \times g for 5 min, concentrated 40 times with an Amicon filtration unit of 10 kDa MW cut-off (Merck KGaA). flTRAIL is a transmembrane protein that was extracted and purified. flTRAIL-BM-MSCs were cultured as aforementioned with the sTRAIL-BM-MSCs or IFN β -BM-MSCs until flTRAIL-BM-MSCs culture reached 80% confluency. Then, flTRAIL-BM-MSCs were harvested and washed twice with PBS. Subsequently, 1×10^6 cells were resuspended in 50 μ l of lysis buffer [Triton X-100 (50 ml), Tris-HCl 1 M pH 7.5 (5 ml), KCl 2 M (12.5 ml), MgCl₂ 1 M (1 ml), DTT (1 μ l, Invitrogen; Thermo Fisher Scientific, Inc.) and a protease inhibitor cocktail (5 μ l; Sigma-Aldrich; Merck KGaA)]. The mixture was adjusted at 500 μ l with ultrapure sterile water, chilled in ice for 20 min, centrifuged at 16,000 \times g at 4°C for 5 min, and the supernatant was collected.

Western blot analysis. The aforementioned protein concentrates were quantified with Bradford reagent (Bio-Rad Laboratories, Inc.). After, 40 μ g protein concentrate (5 μ l) was submitted to 2% sodium dodecyl sulfate (SDS), 4% stacking and 12% resolving polyacrylamide gel electrophoresis (PAGE) at 100 V for 120-150 min and the protein bands were electro-transferred to a 0.45- μ m mesh polyvinylidene fluoride membrane (Bio-Rad Laboratories, Inc.) at 100 V for 60 min. Protein was Electro-transfer to a PVDF membrane. The membrane was blocked for 1 h with 5% skimmed milk in Tris-buffered saline with Tween-20 (TBST) at 4°C. The protein bands of sTRAIL, flTRAIL, or IFN β were identified with rabbit monoclonal antibodies anti-murine TRAIL (1:200; cat. no. ab10516; Abcam) or 1:500 rabbit polyclonal anti-murine IFN β (cat. no. ab85803; Abcam), as primary antibodies, incubated overnight at 4°C. The secondary antibody was an HRP-conjugated anti-rabbit polyclonal antibody (1:10,000; cat. no. W4011; Promega

Corporation), incubated for 2.5 h at 4°C. Dilutions of all antibodies were performed with Tris-buffered saline (TBS buffer) in 5% skimmed milk.

The marked protein bands were revealed with the luminol kit Clarity Western ECL blotting substrate (Bio-Rad Laboratories, Inc.) following the manufacturer's protocol and analyzed with the Molecular Imager Chemidoc XRS+ Imaging System (Bio-Rad Laboratories, Inc.) equipped with the Image Lab software.

Commercial recombinant proteins were used as positive controls in all western blot assays; soluble TRAIL recombinant protein (cat. no. 315-19; PeproTech, Inc.) which consists in the extracellular fraction of murine TRAIL, weighing 20 kDa; ~200 ng of recombinant protein was loaded into the gel well. IFN β standard (cat. no. IF011; Merck KGaA) consisted of recombinant murine IFN β weighing 22 kDa; ~2 kU was loaded into the gel well.

Induction of lymphomas. L5178Y cells (5×10^5) were inoculated in the right gastrocnemius with a 27-gauge syringe. The cells were suspended in 100 μ l of saline solution for a total of 72 female BALB/c mice. The mice exhibited mild discomfort immediately after inoculation; however, no sign of discomfort was observed overnight. The implanted leg of each mouse was measured with a Vernier calibrator to calculate the gastrocnemius volume (mm^3), using the following equation: $\text{Vol} = \pi/6 (L \times W \times h)$; where Vol is the volume of the leg, expressed in mm^3 , π is a radius constant (3.1416), L is the leg's length, measured from the ankle to the knee. W is the width of the thickest portion of the leg, and h is the height, measuring from the rear leg section (gastrocnemius) to the front (tibialis anterior). These measurements were performed every third day throughout the experiment. When legs carrying lymphomas showed an increment in the leg volume of 1-2 mm^3 , mice were implanted with the transduced BM-MSCs.

Implantation of transduced BM-MSCs. Mice with lymphomas were divided into nine groups of eight mice each. Transduced BM-MSCs were implanted to one of these groups (G) as follows: G1, BM-MSCs-sTRAIL; G2, BM-MSCs-IFN β plus-flTRAIL; G3, BM-MSCs-IFN β ; G4, flTRAIL; G5, sTRAIL plus IFN β ; G6, not transduced or naïve BM-MSC plus-IFN β plus-flTRAIL; G7, naïve BM-MSC; G8, mice not implanted with BM-MSCs but injected with isotonic saline; G9, mice not implanted with BM-MSCs. In addition, the experiment was repeated with groups G5, sTRAIL plus IFN β , and G6, not transduced BM-MSC to confirm results. However, mice were reduced to five animals per group with the same characteristics. In all implanted mice, 1×10^6 viable BM-MSCs, suspended in 100 μ l isotonic sterile saline, were distributed into the entire volume of each tumor. The number of BM-MSCs transduced separately with two transgenes or two transgenes plus not transduced MSCs were inoculated with an appropriate proportion of BM-MSCs to sum a total of 1×10^6 cells. For example, G5 mice were implanted with 5×10^5 BM-MSCs-sTRAIL and 5×10^5 -IFN β and mice from G6 were implanted with 3.33×10^5 not transduced BM-MSC, plus 3.33×10^5 BM-MSCs IFN β plus 3.33×10^5 flTRAIL. All inoculations were performed in aseptic conditions with a new, sealed sterile 27-gauge needle for each mouse. Before and throughout the experiments, mice behavior,

their ability to eat and drink, and pain indicators were monitored. When a mouse showed intense suffering as previously described (28), these signs included bent down low ears, orbital tightening, bristly hair, sluggishness, or a lack of response to external stimuli. When all signs were detected, the mouse was euthanized. These animals were considered deceased due to their induced lymphoma. Euthanasia was practiced by cervical dislocation. Tumor volume and mouse weight measuring were performed thrice a week, as at the beginning of the experiment.

Tumor biopsies of ~5 mm^3 were dissected from recently deceased animals. The samples from each lymphoma were preserved with Tissue-Tek optimum cutting temperature (O.C.T.) (Sakura Finetek Europe B.V.), freezing the blocks with liquid nitrogen and stored at -80°C.

Histopathological analysis. Frozen samples were cut with a cryostat (model 2230; Shenyang Roundfin Trade Co., Ltd.), stained with hematoxylin and eosin, and observed with a clear field using a light microscope (model DM IL LED; Leica Microsystems GmbH) at 100-400 amplification diameters. Images were captured with a camera (DFC295; Leica Microsystems GmbH) attached to the microscope.

Analysis of results. The number of deceased mice from all groups was monitored daily. When the last not-implanted mouse with BM-MSCs carrying lymphomas succumbed, the percentage of surviving mice from each group and the number of days elapsed since the lymphoma cells were inoculated were registered.

Statistical analysis. The survival rate was analyzed with a Kaplan-Meier estimator with a Mantel-Cox test to assess statistical significance with SPSS software (SPSS Statistics for Windows; version 22.0; IBM Corp.). Statistical analysis was conducted using GraphPad Prism version 7.00 for Windows (GraphPad Software, Inc.). Differences between the analyzed groups were determined with the t-test and one-way ANOVA (followed by Tukey's post hoc test). $P < 0.05$ was considered to indicate a statistically significant difference.

Ethical considerations. The present study was approved (approval no. B115-005) by the Scientific Research and Bioethics Committee and the Institutional Animal Care Committees of the School of Medicine of the Autonomous University of Nuevo Leon (Monterrey, Mexico). The mice were handled according to the Mexican Standard NOM-062-ZOO-1999. The mice were kept in the animal facility of the Department of Immunology in individually ventilated cages (Lab & Bio) that maintain filtered air flow and a barrier that protects them from contact with external agents. The system records pressure, oxygen, CO $_2$, humidity, temperature, and ammonia concentration. Furthermore, this system maintains all these parameters in uniform conditions. The cages were cleaned every 2-3 days by the technical personnel of the vivarium. The model was euthanized if the tumor exceeded 10% of the normal mouse body weight according to the international manual Institutional Animal Care and Use Committee (2002) and would be euthanized by inhalation of CO $_2$ with subsequent cervical dislocation and monitoring of vital signs. They were




Figure 1. BM-MSCs characterization. (A) BM-MSCs were adherent to the culture flask and presented elongated morphology (scale bar, 100 μ m). They also expressed high mesenchymal markers, such as (B) CD90 and (C) CD105 (scale bar, 100 μ m). In addition, they could differentiate to chondrogenic by (D) Alcian blue staining and calcified areas generated by osteogenic cells with (E) Von Kossa stain. BM-MSCs, bone marrow mesenchymal stem cells.

also euthanized if they showed signs of severe pain according to the Rodent Management Laboratory Manual accepted by the American Association for the Accreditation of Animal Care Laboratories (29): decreased intake of water and food, weight loss (>20%), bristly coat, dry skin, lacerations, posture, abnormal gait, head tilt, lethargy, bloating, diarrhea, seizures, discharge from body orifices and dyspnea. The experimental groups were kept under close care from the day of inoculation until the last mouse in the control group succumbed. The mice succumbed due to tumor growth. However, the mice in the experimental groups that survived until the last mouse in the untreated group were sacrificed on the same day that the last untreated mouse lived.

Results

BM-MSCs express TRAIL and IFN β . BM-MSCs isolated from mice presented fibroblast morphology in culture and were characterized by expression of CD90 and CD105 superficial markers that presented >95% positive cell staining (Fig. 1A-C). In addition, BM-MSCs differentiated to chondroblasts and osteoblasts, showing positivity to Alcian blue and Von Kossa stains, respectively (Fig. 1D and E). A representative field of transduced BM-MSCs is shown in Fig. 2D. All cells fluoresced intensely in green due to expression of the GFP gene and geneticin selection, denoting an efficient integration of each gene construct. The percentage of transduction efficiency of BM-MSCs-sTRAIL and -flTRAIL was 90% and for BM-MSCs-IFN β was 95%. For protein expression, western blot results are

shown in Fig. 2E and F. The protein bands, whose images are demonstrated in Fig. 2E, correspond to sTRAIL and an sTRAIL standard, respectively, with both weighing ~20 kDa (control). The image of flTRAIL, revealing a ladder of five bands; the smallest one weighs ~20 kDa, which matches the 2 soluble TRAIL standard control; however, 4 heavier bands of ~30, ~39, ~45, and ~60 kDa were also revealed. In Fig. 2F, two IFN β bands are demonstrated, one weighing ~22 kDa and a slightly heavier ~24 kDa band. Alongside as control, the recombinant IFN β standard shows a single band weighing ~22 kDa.

BM-MSCs expressing sTRAIL and IFN β reduce solid lymphoma engraftment. On day 7 post-inoculation (PI), a slight inflammation was observed in all inoculated subjects. PI leg volumes on day 9, comparing the non-inoculated and inoculated groups are revealed in Fig. 3; considering one standard deviation as a reference, it displays the totality of the study subjects with tumor engraftment.

First, deceased mice from the untreated group were registered by day 26 PI; therefore, the last tumor measure with full subjects' groups was on day 23 PI. Fig. 4A highlights the most relevant results: the untreated group shows the largest tumor (average 2.5 cm³) and first deceased mouse at day 26 PI; on the other hand, the group with combined treatment of IFN β and sTRAIL showed the smallest tumor (1.2 cm³) by day 23, and the first mouse succumbed by day 29 PI. Notably, separated treatments of both sTRAIL and IFN β also showed considerably smaller tumors (compared with the untreated group) but slightly larger than the combined one (1.3 and 1.5 cm³, respectively).




Figure 2. Lentiviral transduction of BM-MSC. (A-C) Lentiviral vectors were designed to contain (A) sTRAIL, (B) flTRAIL and (C) IFN β . (D) Representative fluorescent images of BM-MSCs transduced with lentiviral vectors; nucleus stained with DAPI (blue) and transduced BM-MSCs expressing GFP protein (green signal). (E and F) Western blot analysis confirming protein expression of (E) flTRAIL and sTRAIL (F) and IFN β in untransfected MSCs and MSCs transduced with a lentivirus that does not contain any of the genes of interest (empty lentiviral vector pLV[Exp]-EGFP:T2A:Puro-EF1Aα; mCherry, Vector Builder). MSCs express each of the genes flTRAIL, sTRAIL and IFN and as positive control the recombinant protein. Actin was used as a loading control. BM-MSCs, bone marrow mesenchymal stem cells; sTRAIL, TRAIL soluble; flTRAIL, TRAIL full length; IFN β , interferon β .

BM-MSC expressing sTRAIL, flTRAIL and IFN β treatments do not affect mice weight. During the study, mice weights were documented. Any mouse that exhibited a loss of $\geq 20\%$ of the baseline weight was withdrawn from the study and euthanized. The weight of all groups during the study is revealed in Fig. 4B; mice showed stable weight by day 19 PI; however, important weight variability was registered thereafter. All mice were carefully observed to detect a disability to eat or drink; however, despite massive tumors, mice were eating and drinking; thus, weight variability was associated with tumor

growth. All subjects gained weight according to the developed tumor mass.

In addition, tumor tissues were analyzed with a light microscope. A section of the tumor of untreated mice was compared with tissue of the inoculated leg of surviving mice. Images of histological sections are revealed in Fig. 5. It was demonstrated how the tumor tissue almost completely displaced muscle tissue (Fig. 5B and D), exhibiting basophilic predominance of lymphocyte (tumoral cell) nuclei, which in contrast to a surviving mouse, most of the tissue was




Figure 3. Leg tumor volumes at day 9. Figure shows differences between leg volumes of inoculated and not inoculated mice. * $P<0.001$ vs. W/O inoculum.

acidophilic with skeletal muscle tissue (Fig. 5A and C). It was also observed that a few nuclei dispersed over the muscle tissue, indicating an active immune reaction. The statistical analysis of the infiltration rate and morphology observed in treated tissues is revealed in Fig. 5E and F. Chi-square showed differences between the control and the treatment group ($P<0.001$); however, in morphology, no statistical differences were identified.

BM-MSCs expressing sTRAIL and IFN β increase survival of mice with solid lymphoma engraftment. The last untreated mouse died at day 41 PI; thus, a cut-off point was established. All groups comparing each treated group against the untreated group were analyzed. In Fig. 6A, a Kaplan-Meier estimator with the most relevant results is demonstrated: 100% of untreated mice succumbed due to the tumor by day 41 PI. On the other hand, the combined treatment of IFN β and sTRAIL showed a 62.5% survival rate. Additionally, the separated groups of IFN β and sTRAIL showed 25 and 50% survival, respectively, in addition to initial tumor mass, which showed a similar result, suggesting an additive effect. The log-rank test showed significant differences between the groups ($P<0.05$). All P-values are included in Table I.

To confirm these results, the combination treatment of BM-MSCs expressing sTRAIL and IFN β was repeated. The results are presented in Fig. 6B. The control treatment of naïve BM-MSCs was added. At first, both treatments reduced tumor growth in the right gastrocnemius; however, near day 20, mice of the groups treated with naïve BM-MSCs presented an increase in tumor volume. On day 36 PI, the last mouse of the naïve BM-MSCs group was euthanized, and 40% of survivors remained in the group treated with sTRAIL plus IFN β . The log-rank test showed significant differences between the groups ($P<0.001$). Mice were kept monitored until day 50; nevertheless, mice did not present visually solid tumors in the right gastrocnemius.

All treatments showed anti-tumorigenic activity to some extent. Independent treatments showed poorer antitumor activity than combined ones. IFN β exhibited the lowest

therapeutic activity with a 25% survival rate, sTRAIL showed 37.5%. Combined treatment showed 37.5% survival rate, indicating a non-additive effect since it remained nearly the same as when treatment was performed with sTRAIL alone. Notably, saline solution had a 25% survival rate. A combined treatment of MSC naïve, IFN β and flTRAIL showed a 50% survival rate, indicating a slight improvement over flTRAIL and IFN β alone, suggesting MSC antitumoral effect.

Discussion

Cancer xenograft *in vivo* murine models have been a frequent approach in numerous research groups; indeed, the chimeric models of human tissue in immunodeficient mice have allowed achievement of tremendous advances and testing several cancer models and treatments (30). The current landscape deems murine models as the cornerstone in biomedical research (31).

MSC approaches in murine cancer models involve the following criteria: first, a cancer model; that is, a tumor-inducing cell line *in vivo* of certain tissue; second, determination of the source of the MSCs, as there are significant phenotypic and genotypic differences among the cells in terms of regenerative capacity, multipotency, isolation yield, and overall behavior within the tumor; third, one or more anti-cancer transgenes to be expressed and delivered; and finally, fourth, a mouse strain according to the aims of the study (32). CD105, CD90 and CD73 are main markers highly expressed by BM-MSCs (33). In the present study, CD105 and CD90 were only evaluated. CD73 expression on MSCs was reported heterogeneity from different sources as adipose tissue, BM, amniotic membrane (34). However, previous research has shown that CD73 has the power to promote cell proliferation, tumor angiogenesis, and has the ability to make tumor cells escape immunological recognition (35), so its evaluation would be very interesting for future studies.

MSCs have been reported to possess homing ability led by chemokines and growth factors from the tumor site. Moreover, this therapeutic effect depends on the capacity of reaching the tumor site, by migration, expression of adhesion molecules, and engraftment in the tumor microenvironment. It has been previously reported that MSCs decrease the incidence of lymphoma tumors and improve survival of C57BL/6 mice when intravenously administered (36). In addition, intraperitoneal administration of MSCs in a disseminated non-Hodgkin's lymphoma murine model increases the overall survival of treated mice (37). Both studies demonstrated MSC homing to tumoral cells. Nevertheless, there is a lack of enough lymphoma studies that determine the complete mechanisms of antitumoral activity of MSC, which opens an important field to research. In the present study, a murine, syngeneic, immunocompetent, lymphoma model treated with BM-MSCs overexpressing TRAIL (soluble fraction or full-length protein) and IFN β by intratumoral inoculation was employed to elucidate if unmodified MSC would exert a pro-tumoral or anti-tumoral effect and if such an effect would be reverted or enhanced, respectively by the transgenes alone or combined.

The tumor microenvironment is determinant in tumor progression as T and B lymphocytes are strongly influenced




Figure 4. Murine tumor model. (A) Tumor mass showed differences between groups, with the ones treated with combination of sTRAIL and IFN β exhibiting the smallest volumes. (B) Mice weight remained unaffected during the experiment. sTRAIL, TRAIL soluble; flTRAIL, TRAIL full length; IFN β , interferon β .




Figure 5. Tumor histological sections. (A and C) Tumors treated with sTRAIL and IFN β . (B and D) Tumors without treatment. (E and F) Semiquantitative analysis according to (E) cellular infiltration grade and (F) morphology in treated tissues and control. Scale bar, 25 μ m. ** P <0.001. sTRAIL, TRAIL soluble; IFN β , interferon β .

by it and vice versa, affecting other cells. T-cells are the most important line of defense regarding cancer development; nonetheless, tumors can produce TGF- β , which favors T cell conversion to regulatory T-cell, which exhibits protumor effects by immunosuppression (38).

B-cell subsets have demonstrated cooperative or opposite roles within the tumors. Immunosuppressive regulatory B cells or tumor-infiltrating lymphocytes have protumor effects as they tend to be up to 25% of cells within the tumor mass, can produce lymphotoxin, an angiogenesis-inducing protein (39), and secrete antibodies against tumor-specific antigens (such as p53) (40) with variable outcomes. On the other hand, there are also effector B-cells with antitumor effects by antigen presentation, CD4 T-cell activation, and macrophage conversion to antitumoral M1 phenotype (41). In aims for an improved understanding of cancer development and treatments, in our

opinion, a homogenous, syngeneic model provides substantial advantages.

To the best of our knowledge, there are no reports of lymphoma immunocompetent models with combined TRAIL (soluble fraction and complete) and IFN β treatments. Soluble TRAIL required several accessories to be secreted extracellularly to exert its intended function: an isoleucine zipper to facilitate ligand trimerization (25), a signal sequence-derived *Gaussia princeps* luciferase (26) to conduct protein extraction, and a furin cleavage site to eliminate all upstream accessory sequences (24); all transgenes proved to be recognizable as they were easily detected by western blotting. flTRAIL showed 5 bands (weighing ~20, ~30, ~39, ~45 and ~60 kDa), which differs from a 24-25 kDa expected weight; however, similar reports suggested a glycosylated version of the protein (27) or possible oligomerization of the ligand. Additionally, a ~20 kDa




Figure 6. Kaplan-Meier curves. (A) First model with all treatments. (B) Second model with sTRAIL and IFN β treatment and MSC naïve. * $P < 0.05$ and ** $P < 0.001$ compared with the untreated group. sTRAIL, TRAIL soluble; IFN β , interferon β ; MSC, mesenchymal stem cell.

band suggests the expression of soluble TRAIL as well. IFN β showed 2 bands (~22 and ~24 kDa), similar to flTRAIL; the smaller band matched the recombinant standard, and the observed ~24 kDa band is probably a glycosylated version of the protein.

TRAIL has been examined in numerous studies and clinical trials due to its unique property of targeting transformed cells, but its short half-life and toxicity make it impractical; thus, the need for a dose-based therapy by cell delivery is plausible. Soluble TRAIL fraction is normally secreted by the cell to procure DR4⁺ or DR5⁺ cells more easily than the complete protein; thus, flTRAIL is anchored to the cell membrane. Therefore, it requires a markedly closer cell-cell approach to trigger apoptosis. Notably, Yuan *et al* (27) demonstrated that flTRAIL exhibited a more efficient cell-killing effect in TRAIL sensitive and resistant cell lines *in vitro*. Conversely, in the present *in vivo* study, sTRAIL resulted in the best single-gene treatment in tumor-reducing effects (with an average volume of 1.4 cm³ leg-tumor size as opposed to flTRAIL with 1.5 cm³) and survivability (50% compared with 37.5% for flTRAIL). This finding could be due to inherent differences between *in vitro* and *in vivo* models and protein presentation, as multimers of flTRAIL are more likely as they are suspended in a controlled environment. MSCs administered intravenously or in another form of distant administration require a large number of cells due to loss and death on the way to the tumor site (4,11); the majority get trapped in capillaries and in the lungs owing to their large size and expression of adhesion molecules (2). Despite this, the ones that arrive at the tumor site could develop activity, which in turn is enhanced through genetic modification to express cytokines and pro-apoptotic

Table I. Survival significant differences between treated and non-treated groups.

Treatment	P-value
sTRAIL	0.017
flTRAIL + IFN β	0.068
IFN β	0.170
flTRAIL	0.072
sTRAIL + IFN β	0.008
MSC naïve + IFN β + flTRAIL	0.042
MSC naïve	0.038
Saline solution	0.309

MSC, mesenchymal stem cell; sTRAIL, TRAIL soluble; flTRAIL, TRAIL full length; IFN β , interferon β .

proteins (11-13). By contrast, intratumoral-inoculated cells are significantly more restricted, relying only on cells close to the tumor parenchyma puncture site; additionally, the soluble TRAIL construct was designed to be secreted abundantly and perfused more efficiently through the tumor. Furthermore, to reduce variation during the administration of the MSCs in each of the experimental groups, the inoculation of cells was performed less than 1 h after cell counting further avoiding any reduction in viability.

IFN β has been intensively studied in several models (21,42,43) with abundant evidence of its anticancer activity, namely, immune system stimulation, angiogenesis, and malignant cell inhibition using S-phase accumulation (44-46). In the present study, IFN β treatment dealt relatively poor tumor-reducing activity while administered alone, as it exhibited only 25% of survival rate. Notably, combined treatment with sTRAIL showed a 62.5% survival rate, which surpasses both single-gene treatments (sTRAIL and IFN β), suggesting an additive effect.

IFN β was unexpectedly ineffective. Interferons type I have direct effects on T-cells; for instance, IFN β -based treatment is the first choice to treat multiple sclerosis by modulation of T cell activity (47); therefore, malignant T cells are inherently influenced by it. However, the specific nature of such effects is unclear as current information is notably paradoxical due to the complex effect IFN β exerts on T cells (48). To elucidate this subject goes beyond the aim of the present study. On the other hand, IFN β can induce apoptosis by upregulation and enhanced sensitivity of endogenous TRAIL and upregulation of TRAIL-R1 and TRAIL-R2 in cancer cell lines; moreover, there is evidence that IFN β induces a lengthened S-phase which also potentiates TRAIL's apoptosis-inducing effect in nasopharyngeal (49), and cervical carcinomas (50).

It is well known that more than caspase cascade activation, TRAIL can also modulate NF- κ B signaling (51,52), which is controversial as NF- κ B can upregulate the expression of survival factors such as members of the apoptosis family inhibitor and Bcl-xL (53). Conversely, TRAIL-dependent NF- κ B activation triggers apoptosis rather than survival in epithelial cell lines and T cells (54,55). In addition, TRAIL

sensitivity can be upregulated by IFNs by overexpression of the TRAIL-R2 DR5 (56-58). IFN β induces TRAIL-R2 expression in ME-180 cells in the S phase (50), and in melanoma and breast cancer cells, IFN β induces apoptosis by an extrinsic pathway dependent on TRAIL expression. TRAIL overexpression is a Stat1 dependent process associated with activation of the TRAIL promoter (59).

Related to the MSC treatment, first, 50% survival was observed, but in a second experiment, recurrence and tumor growth after day 26 was identified. This finding showed that MSCs present immunoregulatory properties, as they can inhibit T-cell proliferation and migratory properties and are resistant to natural killer cell-mediated cytotoxicity. Those attributes contribute to the application of MSC-based delivery of therapeutic genes to solid tumors (60). However, MSC could improve cancer development by increasing the expression of immunosuppressive cytokines such as IL-10 when activated with signals from the tumor microenvironment (22,61,62). In addition, it was observed that the saline solution (placebo) group showed a 25% survival rate, which was reasonably expected considering all mice were immunocompetent. Mice reached immune maturity, which could be explained as a local immunological reaction due to intramuscular solution inoculation that resulted in mild bleeding and muscle inflammation, acting as a local adjuvant.

By day 41 PI, the surviving mice reduced the tumor to the point of being imperceptible. The histological analysis of the untreated mice showed almost no proper muscle tissue but instead was completely saturated with lymphoid cells; by contrast, treated mice showed seemingly healthy muscle tissue, with histologically normal muscle fibers and few scattered lymphoid cells. This finding bifurcates into two rather simplistic yet actual possibilities: i) The main component of the tumor microenvironment is tumor infiltrating lymphocytes of different phenotypes as helper and cytotoxic T cells; these cells could be normal, healthy lymphoid cells due to the immune surveillance induced by the malignant cells, which in this scenario, are seemingly depleted; or ii) Remaining transformed lymphoma cells within the muscle tissue represent an ongoing immunological process rather than a terminated one (63,64). Both scenarios could be elucidated by finer cell characterization, a longer-term observation period to detect relapse, and larger subject groups. In addition, the combined treatment of sTRAIL and IFN β did recover the tissue morphology mainly due to extended tumor damage. Thus, the mechanism of tissue repair after cancer elimination needs improvement.

In conclusion, the present findings demonstrated that MSCs are effective anti-lymphoma vehicles, as non-treated mice developed massive tumor masses and succumbed. Moreover, in this model, sTRAIL had improved tumor-reducing effects, and IFN β enhanced it.

Acknowledgements

The authors would like to thank Dr Sergio Lozano (Autonomous University of Nuevo Leon, Monterrey, Mexico) for reviewing the manuscript.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

AGQR and CAGV contributed to designing, performing experiments, analysis and discussion of results. HMR helped to design of experiments, wrote, analyzed and corrected the manuscript. SSF designed the experiments, performed literature analysis and discussion of results. MCSC and AYLH helped in the management and in the care with murine model. ASD helped in the standardization of immunohistochemistry and with the software of the fluorescence microscope. GPR helped with statistical analysis. RMDOL contributed to designing of transgenes of lentivirus. JFI edited the text, analyzed the results and reviewed the final manuscript. ENGT contributed to the design of experiments, analysis of the results, discussion and correction of the manuscript. AGQR, CAGV and ENGT confirm the authenticity of all the raw data. All authors have read and approved the final version of the manuscript.

Ethics approval and consent to participate

The present study was approved (approval no. BI15-005) by the Scientific Research and Bioethics Committee and the Institutional Animal Care Committees of the School of Medicine of the Autonomous University of Nuevo Leon (Monterrey, México).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Urruticoechea A, Alemany R, Balart J, Villanueva A, Viñals F and Capellá G: Recent advances in cancer: An Overview. *Curr Pharm Des* 16: 3-10, 2010.
2. Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L and Emami B: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. *N Engl J Med* 326: 1593-1598, 1992.
3. Singh P, Pandit S, Mokkapati VRSS, Garg A, Ravikumar V and Mijakovic I: Gold nanoparticles in diagnostics and therapeutics for human cancer. *Int J Mol Sci* 19: 1979, 2018.
4. Baetke SC, Lammers T and Kiessling F: Applications of nanoparticles for diagnosis and therapy of cancer. *Br J Radiol* 88: 20150207, 2015.
5. Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. *Nat Rev Drug Discov* 16: 203-221, 2017.
6. Iorio MV and Croce CM: MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review. *EMBO Mol Med* 4: 143-159, 2012.
7. Ling H, Fabbri M and Calin GA: MicroRNAs and other non-coding RNAs as targets for anticancer drug development. *Nat Rev Drug Discov* 17: 139-148, 2013.
8. Loebinger M, Sage E, Davies D and Janes S: TRAIL-expressing mesenchymal stem cells kill the putative cancer stem cell population. *Br J Cancer* 103: 1692-1697, 2010.

9. Liu X, Hu J, Li Y, Cao W, Wang Y, Ma Z and Li F: Mesenchymal stem cells expressing interleukin-18 inhibit breast cancer in a mouse model. *Oncol Lett* 15: 6265-6274, 2018.
10. Matosevic S: Viral and nonviral engineering of natural killer cells as emerging adoptive cancer immunotherapies. *J Immunol Res* 2018: 4054815, 2018.
11. Friedenstein AJ, Gorskaja JF and Kulagina NN: Fibroblast precursors in normal and irradiated mouse hematopoietic organs. *Exp Hematol* 4: 267-274, 1976.
12. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S and Marshak DR: Multilineage potential of adult human mesenchymal stem cells. *Science* 284: 143-147, 1999.
13. Igura K, Zhang X, Takahashi K, Mitsuru A, Yamaguchi S and Takahashi TA: Isolation and characterization of mesenchymal progenitor cells from chorionic villi of human placenta. *Cytotherapy* 6: 543-553, 2004.
14. Karp JM and Leng Teo GS: Mesenchymal stem cell homing: The devil is in the details. *Cell Stem Cell* 4: 206-216, 2009.
15. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R and Weinberg RA: Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. *Nature* 449: 557-563, 2007.
16. Shinagawa K, Kitadai Y, Tanaka M, Sumida T, Kodama M, Higashi Y, Tanaka S, Yasui W and Chayama K: Mesenchymal stem cells enhance growth and metastasis of colon cancer. *Int J Cancer* 127: 2323-2333, 2010.
17. Yu JM, Jun ES, Bae YC and Jung JS: Mesenchymal stem cells derived from human adipose tissues favor tumor cell growth in vivo. *Stem Cells Dev* 17: 463-473, 2008.
18. Pan G, O'Rourke K, Chinnaiyan A, Gentz R, Ebner R, Ni J and Dixit V: The receptor for the cytotoxic ligand TRAIL. *Science* 276: 111-113, 1997.
19. Wong SHM, Kong WY, Fang CM, Loh HS, Chuah LH, Abdullah S and Ngai SC: The TRAIL to cancer therapy: Hindrances and potential solutions. *Crit Rev Oncol Hematol* 143: 81-94, 2019.
20. Nicolini A, Carpi A and Rossi G: Cytokines in breast cancer. *Cytokine Growth Factor Rev* 17: 325-337, 2006.
21. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ and Andreeff M: Bone marrow-derived mesenchymal stem cells as vehicles for interferon- β delivery into tumors. *Cancer Res* 62: 3603-3608, 2002.
22. Gonzalez-Villarreal C, Rodriguez M and Said-Fernández S: How desirable and undesirable features of naïve or genetically reengineered mesenchymal stem cells are being considered in preclinical or clinical assays. *J BUON* 22: 812-830, 2017.
23. Qin JY, Zhang L, Clift KL, Hultner I, Xiang AP, Ren BZ and Lahn BT: Systematic comparison of constitutive promoters and the doxycycline-inducible promoter. *PLoS One* 5: 3-6, 2010.
24. Kim MH, Billiar TR and Seol DW: The secretable form of trimeric TRAIL, a potent inducer of apoptosis. *Biochem Biophys Res Commun* 321: 930-935, 2004.
25. Yan C, Li S, Li Z, Peng H, Yuan X, Jiang L, Zhang Y, Fan D, Hu X, Yang M and Xiong D: Human umbilical cord mesenchymal stem cells as vehicles of CD20-specific TRAIL fusion protein delivery: A double-target therapy against non-Hodgkin's lymphoma. *Mol Pharm* 10: 142-151, 2013.
26. Stern B, Olsen LC, Tröbe C, Ravneberg H and Pryme IF: Improving mammalian cell factories: The selection of signal peptide has a major impact on recombinant protein synthesis and secretion in mammalian cells. *Trends Cell Mol Biol* 10: 19-24, 2007.
27. Yuan Z, Kolluri KK, Sage EK, Gowers KH and Janes SM: Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand is superior to soluble type for cancer therapy. *Cytotherapy* 17: 885-896, 2015.
28. Langford DJ, Bailey AL, Chanda ML, Clarke SE, Drummond TE, Echols S, Glick S, Ingrao J, Klassen-Ross T, Lacroix-Fralish ML, *et al*: Coding of facial expressions of pain in the laboratory mouse. *Nat Methods* 7: 447-449, 2010.
29. Committee on Rodents, Institute of Laboratory Animal Resources, Commission on Life Sciences and the National Research Council: *Laboratory Animal Management*, National Academies Press, Washington, D.C., USA, pp 99, 1996.
30. Bankert RB, Egilmez NK and Hess SD: Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies. *Trends Immunol* 22: 386-393, 2001.
31. Haouzi P: Murine models in critical care research. *Crit Care Med* 39: 2290-2293, 2011.
32. Frese K and Tuveson D: Maximizing mouse cancer models. *Nat Rev Cancer* 7: 654-658, 2007.
33. Boxall SA and Jones E: Markers for characterization of bone marrow multipotential stromal cells. *Stem Cells Int* 2012: 975871, 2012.
34. Darzi S, Werkmeister JA, Deane JA and Gargett CE: Identification and characterization of human endometrial mesenchymal stem/stromal cells and their potential for cellular therapy. *Stem Cells Transl Med* 5: 1127-1132, 2016.
35. Li Q, Hou H, Li M, Yu X, Zuo H, Gao J, Zhang M, Li Z and Guo Z: CD73⁺ Mesenchymal stem cells ameliorate myocardial infarction by promoting angiogenesis. *Front Cell Dev Biol* 9: 637239, 2021.
36. Song N, Gao L, Qiu H, Huang C, Cheng H, Zhou H, Lv S, Chen L and Wang J: Mouse bone marrow-derived mesenchymal stem cells inhibit leukemia/lymphoma cell proliferation *in vitro* and in a mouse model of allogeneic bone marrow transplant. *Int J Mol Med* 36: 139-149, 2015.
37. Secchiero P, Zorzet S, Tripodo C, Corallini F, Melloni E, Caruso L, Bosco R, Ingrao S, Zavan B and Zauli G: Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-hodgkin's lymphoma xenografts. *PLoS One* 5: e11140, 2010.
38. Tu E, Chia PZC and Chen W: TGF β in T cell biology and tumor immunity: Angel or devil? *Cytokine Growth Factor Rev* 25: 423-435, 2014.
39. Yuen GJ, Demissie E, Pillai S and Burnet M: B lymphocytes and cancer: A love-hate relationship. *Trends Cancer* 2: 747-757, 2017.
40. Soussi T: p53 Antibodies in the sera of patients with various types of cancer: A review. *Cancer Res* 60: 1777-1788, 2000.
41. Sharonov GV, Serebrovskaya EO, Yuzhakova DV, Britanova OV and Chudakov DM: B cells, plasma cells and antibody repertoires in the tumour microenvironment. *Nat Rev Immunol* 20: 294-307, 2020.
42. Lei H, Furlong PJ, Jin HR, Mullins D, Cantor R, Fraker DL and Spitz FR: AKT activation and response to interferon- β in human cancer cells. *Cancer Biol Ther* 4: 709-715, 2005.
43. Ren C, Kumar S, Chanda D, Kallman L, Chen J, Mountz JD and Ponnazhagan S: Cancer gene therapy using mesenchymal stem cells expressing interferon- β in a mouse prostate cancer lung metastasis model. *Gene Ther* 15: 1446-1453, 2008.
44. Dong Z, Greene G, Pettaway C, Dinney CP, Eue I, Lu W, Bucana CD, Balbay MD, Bielenberg D and Fidler IJ: Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-beta. *Cancer Res* 59: 872-879, 1999.
45. Pestka S and Langer JA: Interferons and their actions. *Ann Rev Biochem* 56: 727-777, 1987.
46. Qin X, Runkel L, Deck C, Dedios C and Barsom J: Interferon-beta induces S phase accumulation selectively in human transformed cells. *J Interf Cytokine Res* 17: 355-367, 1997.
47. Kavrochorianou N, Markogiannaki M and Haralambous S: IFN- β differentially regulates the function of T cell subsets in MS and EAE. *Cytokine Growth Factor Rev* 30: 47-54, 2016.
48. Teige I, Liu Y and Issazadeh-Navikas S: IFN- β Inhibits T cell activation capacity of central nervous system APCs. *J Immunol* 177: 3542-3553, 2006.
49. Makowska A, Wahab L, Braunschweig T, Kapetanakis NI, Vokuhl C, Denecke B, Shen L, Busson P and Kontny U: Interferon beta induces apoptosis in nasopharyngeal carcinoma cells via the TRAIL-signaling pathway. *Oncotarget* 9: 14228-14250, 2018.
50. Vannucchi S, Chiantore MV, Fiorucci G, Percario ZA, Leone S, Affabris E and Romeo G: TRAIL is a key target in S-phase slowing-dependent apoptosis induced by interferon- β in cervical carcinoma cells. *Oncogene* 24: 2536-2546, 2005.
51. Yang J, LeBlanc FR, Dighe SA, Hamele CE, Olson TL, Feith DJ and Loughran TP: TRAIL mediates and sustains constitutive NF- κ B activation in LGL leukemia. *Blood* 131: 2803-2815, 2018.
52. Mühlenbeck F, Schneider P, Bodmer JL, Schwenzer R, Hauser A, Schubert G, Scheurich P, Moosmayer D, Tschopp J and Wajant H: The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation. *J Biol Chem* 275: 32208-32213, 2000.
53. Wang CY, Guttridge DC, Mayo MW and Baldwin AS: NF- κ B induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. *Mol Cell Biol* 19: 5923-5929, 1999.
54. Baetu TM, Kwon H, Sharma S, Grandvaux N and Hiscott J: Disruption of NF- κ B signaling reveals a novel role for NF- κ B in the regulation of TNF-related apoptosis-inducing ligand expression. *J Immunol* 167: 3164-3173, 2001.

55. Shetty S, Brown Gladden J, Henson ES, Hu X, Villanueva J, Haney N and Gibson SB: Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFkappaB activation in epithelial derived cell lines. *Apoptosis* 7: 413-420, 2002.
56. Sedger LM, Shows DM, Blanton RA, Peschon JJ, Goodwin RG, Cosman D and Wiley SR: IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. *J Immunol* 163: 920-926, 1999.
57. Meng RD and El-Deiry WS: P53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma. *Exp Cell Res* 262: 154-169, 2001.
58. Shigeno M, Nakao K, Ichikawa T, Suzuki K, Kawakami A, Abiru S, Miyazoe S, Nakagawa Y, Ishikawa H, Hamasaki K, *et al*: Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation. *Oncogene* 22: 1653-1662, 2003.
59. Choi EA, Lei H, Maron DJ, Wilson JM, Barsoum J, Fraker DL, El-Deiry WS and Spitz FR: Stat1-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand and the cell-surface death signaling pathway by interferon beta in human cancer cells. *Cancer Res* 63: 5299-5307, 2003.
60. Bao Q, Zhao Y, Niess H, Conrad C, Schwarz B, Jauch KW, Huss R, Nelson PJ and Bruns CJ: Mesenchymal stem cell-based tumor-targeted gene therapy in gastrointestinal cancer. *Stem Cells Dev* 21: 2355-2363, 2012.
61. Taraballi F, Pasto A, Bauza G and Varner C: Immunomodulatory potential of mesenchymal stem cell role in diseases and therapies: A bioengineering prospective. *J Immunol Regen Med* 4: 100017, 2019.
62. Monteran L and Erez N: The Dark side of fibroblasts: Cancer-Associated fibroblasts as mediators of immunosuppression in the tumor microenvironment. *Front Immunol* 10: 1835, 2019.
63. Yu P and Fu YX: Tumor-infiltrating T lymphocytes: Friends or foes? *Lab Invest* 86: 231-245, 2006.
64. Badalamenti G, Fanale D, Incorvaia L, Barraco N, Listì A, Maragliano R, Vincenzi B, Calò V, Iovanna JL, Bazan V and Russo A: Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone? *Cell Immunol* 343: 103753, 2019.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.